ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
Àú¾ËÄÄêÆÚ´ý£¬µÚ57½ìÅ·ÖÞ¶¾Àíѧ¼ÒºÍÅ·ÖÞ¶¾Àíѧ»á´ó»á£¨57TH CONGRESS OF THE EUROPEAN SOCIETIES OF TOXICOLOGY£¬EUROTOX 2023£©ÖÕÓڻعéÏßÏ£¬ÔÚ˹ÂåÎÄÄáÑǬ²¼¶ûÑÅÄÇÈÈÁÒ¾ÙÐС£
±¾´Î´ó»áÓÉ˹ÂåÎÄÄáÑǶ¾Àíѧ»áÖ÷Àí£¬Ö÷ÌâÊÇ£ºToxicology ¨C multidisciplinary science leading to safer and sustainable life£¨¶¾Àíѧ--ÒýÁì¸üÇå¾²ºÍ¿ÉÒ»Á¬µÄ¶àѧ¿Æ¿ÆÑ§£©¡£º¸ÇÏÖ´ú¶¾ÀíѧµÄ¶à½Ç¶ÈÒéÌ⣬²¢»ùÓÚ¶¾ÀíѧµÄÆÕ±éÐԺͿçѧ¿ÆÏàÖúµÄÖ÷ÒªÐÔ£¬Õö¿ª·ÖÏíºÍ×êÑС£
ÈÕÆÚ | 2023Äê9ÔÂ10-13ÈÕ
ËùÔÚ | ¬²¼¶ûÑÅÄÇ£¬Ë¹ÂåÎÄÄáÑÇ
×ðÁú¿Ê±Õ¹Ì¨ |#45
Ò©ÎïµÄ¶¾ÐÔÆÀ¹ÀÊÇÒ©Î↑·¢Àú³ÌÖкÜÊÇÖ÷ÒªµÄÒ»»·¡£Ëæ×ÅÊÖÒÕǰ½ø£¬Ñо¿Ö°Ô±ÉîÈë¶¾Àí»úÖÆ£¬Ò»Ö±¸ÄÉÆ¶¾ÀíѧÑо¿ÖеÄй¤¾ßºÍÕ½ÂÔ£¬ÒÔïÔÌÒ©Î↑·¢ÖÐÓëÇå¾²Ïà¹ØµÄÏûºÄ¡£¶¾ÀíѧÔÚÁÙ´²Ç°µÄÄ¿µÄÒ²²»ÔÙÊǼòÆÓµÄ¡°Ç°¸ººÉ¡±ÏûºÄ£¬»¹½«Äܹ»¼õÇáÒ©Î︱×÷Ó㬿ª·¢¸üÇå¾²µÄÉúÎï±ê¼ÇÎïÄÉÈëÑо¿¹æÄ££¬´Ó¶øÎªÒ©ÎïÁÙ´²ÀÖ³ÉÔöÌíÒ»·Ý¿ÉÄÜÐÔ¡£
´Ë´Î´ó»á°²ÅÅÁËһϵÁо«²ÊµÄѧÊõÄÚÈÝ£¬×ðÁú¿Ê±¾«Ñ¡ÁËÖØµã±¨¸æÐÅÏ¢£¬¹©Äú²Î¿¼¡£
°¢Æ¬ÀàÒ©ÎïÏà¹Ø¶¾ÐÔ£º´ÓºôÎüÒÖÖÆµ½ÓÃÒ©¹ýÁ¿Ê¢Ðв¡
½²ÕߣºBruno M¨¦garbane (FR)
ʱ¼ä£ºMonday, 11 September£¬08h30 ¨C 09h30
̻¶×é»á³¹µ×¸Ä±ä¶¾Àíѧʵ¼ùÂð£¿
EUROTOX±çÊÖ: Robert Barouki (Universit¨¦ de Paris, FR)
SOT±çÊÖ: Robert Wright (Icahn School of Medicine at Mount Sinai, NY, US)
ʱ¼ä£ºMonday, 11 September£¬13h00 ¨C 14h00
»úÖÆµÄÖ÷ÒªÐÔ£º µ¼ÏòÒò¹û¿´·¨£¬ÌṩΣº¦ÆÀ¹ÀÒÀ¾Ý
½²ÕߣºLois D. Lehman-McKeeman (Bristol Myers Squibb, NJ, US)
ʱ¼ä£ºTuesday, 12 September£¬08h30 ¨C 09h30
ÃÔÄãÖíµÄת»¯ÖªÊ¶£ºïÔÌÔÚ·ÇÁÙ´²Çå¾²ÐÔÑо¿ÖÐʹÓ÷ÇÈËÁ鳤ÀදÎïµÄ³ö·
½²ÕߣºSteven van Cruchten (University of Antwerp, BE)
ʱ¼ä£ºTuesday, 12 September£¬13h00 ¨C 14h00
S01: Human biomonitoring ¨C a view to the future based on current achievements
ÈËÀàÉúÎï¼à²â--»ùÓÚÏÖÓÐÏ£ÍûµÄδÀ´Õ¹Íû
S03: Current and future perspectives on the extended one-generation reproductive toxicity study (EOGRTS)
ÑÓÉìÒ»´úÉúÖ³¶¾ÐÔ¼ì²â£¨EOGRTS£©µÄÄ¿½ñÇéÐÎÓëδÀ´Õ¹Íû
S05: Consideration of the endogenous exposome in risk assessment
Σº¦ÆÀ¹ÀÖжÔÄÚÔ´ÐÔ̻¶ÌåÒòËØµÄ˼Á¿
S07: Involvement of mitochondria in adverse drug reactions
ÏßÁ£Ìå¼ÓÈëÒ©Îï²»Á¼·´Ó¦
S09: Current use of NAMS/alternatives in DART testing
ÏÖÔÚÔÚ DART ²âÊÔÖÐʹÓõÄNAMS/Ìæ»»ÒªÁì
S11: Contact allergen potency: the missing piece in the huge puzzle of alternative methods
½Ó´¥¹ýÃôÔЧÁ¦£ºÌæ»»ÒªÁìµÄ¾ÞºÆ½ÙÌâÖÐȱʧµÄÒ»»·
S12: Finding synergies for 3Rs ¨C toxicokinetics, physiologically-based kinetic (PBK) models and read-across
ѰÕÒ 3R µÄÐͬ×÷ÓÃ--¶¾´ú¶¯Á¦Ñ§¡¢»ùÓÚÐÄÀíѧµÄ¶¯Á¦Ñ§ (PBK) Ä£×ӺͶÁÊý½»Ö¯
S13: Acceptance and use of in vitro methods: a perspective from various chemical sectors
ÌåÍâÒªÁìµÄÓ¦ÓãºÀ´×Ô²î±ð»¯Ñ§ÁìÓòµÄÊÓ½Ç
S14: NAM mechanistic information for the risk assessment of chemical mixtures
ÓÃÓÚ»¯Ñ§»ìÏýÎïΣº¦ÆÀ¹ÀµÄNAM»úÀíÐÅÏ¢
S15: Next generation risk assessment of food chemicals, environmental contaminants and pharmaceuticals using open-source modelling platforms: perspectives from regulatory agencies, academia and industry
ʹÓÿªÔ´½¨Ä£Æ½Ì¨¶ÔʳÎﻯѧƷ¡¢ÇéÐÎÎÛȾÎïºÍÒ©Æ·¾ÙÐÐÏÂÒ»´úΣº¦ÆÀ¹À£ºÀ´×Ôî¿Ïµ»ú¹¹¡¢Ñ§Êõ½çºÍ¹¤Òµ½çµÄ¿´·¨
S16: Organ-on-a-chip and the developing role in early drug development
Æ÷¹ÙоƬºÍÔÚÔçÆÚÒ©Î↑·¢ÖÐʩչµÄ×÷ÓÃ
S17: Critical organs and exposure windows for developmental immunotoxicity assessment
·¢ÓýÆÚÃâÒß¶¾ÐÔÆÀ¹ÀµÄÒªº¦Æ÷¹ÙºÍ̻¶´°¿Ú
S20: Are diseases and conditions related to hormone imbalance really increasing?
ÓëºÉ¶ûÃÉʧµ÷Óйصļ²²¡ºÍ²¡Ö¢ÕæµÄÔÚÔöÌíÂð£¿
S21: Environmental chemical mixtures and cancer hallmarks ¨C new developments and open questions
ÇéÐλ¯Ñ§»ìÏýÎïºÍ°©Ö¢±ê¼Ç--ÐÂÏ£ÍûºÍδ¾öÎÊÌâ
S22: Role of immunity and contribution of immunotoxicity in the identification of non-genotoxic carcinogens
ÃâÒßµÄ×÷ÓúÍÃâÒß¶¾ÐÔÔÚÈ·¶¨·ÇÒÅ´«¶¾ÐÔÖ°©ÎïÖеÄТ˳
ʱ¼ä£º2024Äê09ÔÂ08ÈÕ-11ÈÕ
ËùÔÚ£ºTivoli Congress Center, Copenhagen, Denmark
×ðÁú¿Ê±Õ¹Î»£º43
ʱ¼ä£º2025Äê9ÔÂ14-17ÈÕ
ËùÔÚ£ºMegaron Concert Hall, Athens, Greece
չλ£º#A559